Details of a Researcher - Hattori, Yutaka

Papers - Hattori, Yutaka

Division display 21 - 40 of about 91 ／ All the affair displays >>

HATTORI YUTAKA

臨床血液 (日本血液学会) 56 ( 11 ) 2311 - 2317 2015

Research paper (scientific journal), Joint Work, Accepted, ISSN 0485-1439

CD138 has been considered to be strongly expressed in multiple myeloma cells. However, CD138+ cells were decreased in some patients during the course of treatment. To clarify the clinical significance of this finding, we evaluated the correlations of CD138 levels with laboratory data employing flow cytometry. We found that CD138+ cells were decreased in 12 patients during treatment and were retained in the remaining 105 patients throughout their clinical courses. For nine (75%) patients in the CD138+ cells reduced group, median survival time was 25 months after the reduction in CD138+ cells was detected, and all nine died of myeloma. Furthermore, extramedullary lesions and specific cytogenetic abnormalities [del(17p), t(4;14), amplification of c-MYC] were observed in some patients when the number of CD138+ cells started to decrease. Interestingly, 2 of 3 patients who survived until the end of observation period showed re-increase in their CD138+ levels. Taking these observations together, it is unclear whether reduction of the number of CD138+ cells is associated with a poor prognosis and resistance to drugs. However, if treatment does not produce a reincrease in CD138+ levels, long term survival might be difficult to achieve.

Access to Document (DOI)

IMiDsの作用機序と催奇形性

HATTORI YUTAKA

腫瘍内科 (科学評論社) 14 ( 6 ) 596 - 600 2014.12

Single Work

Detection of leukemia associated antigen-specific cytotoxic T cells in a patient with Philadelphia chromosome-positive leukemia during treatment with dasatinib.

Matsushita M, Tonegawa K, Mori T, Kohashi S, Kato J, Matsuki E, Okamoto S, Hattori Y.

Leukemia Lymphoma (INFORMA HEALTHCARE) 55 ( 3 ) 722 - 724 2014.03

Research paper (scientific journal), Joint Work, Accepted, ISSN 1042-8194

Access to Document (DOI)

IMWG consensus on risk stratification in multiple myeloma.

4. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group (Hattori Y, et al.).

Leukemia (NATURE PUBLISHING GROUP) 28 ( 2 ) 269 - 277 2014.02

Joint Work, ISSN 0887-6924

Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.

Access to Document (DOI)

Codon 72 Polymorphism of TP53 Gene Is a Novel Prognostic Marker for Thalidomide Therapy in Multiple Myeloma.

Hattori Y, Ikeda Y, Suzuki Y, Ichikawa D, Matsushita M.

British Journal of Haematology 165 ( 5 ) 728 - 731 2014.01

Research paper (scientific journal), Joint Work, Accepted

多発性骨髄腫に対する新規薬剤の二次性骨髄異形成症候群・急性白血病発症への影響

HATTORI YUTAKA

臨床血液 (日本血液学会) 55 ( 4 ) 428 - 435 2014

Research paper (scientific journal), Joint Work

Codon 72 polymorphism of TP53 gene is a novel prognostic marker for therapy in multiple myeloma

Yutaka Hattori, Yurika Ikeda, Yuya Suzuki, Daiju Ichikawa, Maiko Matsushita

British Journal of Haematology (Blackwell Publishing Ltd) 165 ( 5 ) 728 - 731 2014

Accepted, ISSN 1365-2141

Access to Document (DOI)

A Myeloma Cell Line Established from a Patient Refractory to Thalidomide Therapy Revealed High-Risk Cytogenetic Abnormalities and Produced Vascular Endothelial Growth Factor.

Hattori Y, Du W, Yamada T, Ichikawa D, Matsunami S, Matsushita M.

Blood Cancer J 3 e115 2013.05

Research paper (scientific journal), Joint Work

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Fernández de Larrea C, Kyle RA, et al.; International Myeloma Working Group (Hattori Y, et al.).

Leukemia (NATURE PUBLISHING GROUP) 27 ( 4 ) 780 - 791 2013

Research paper (scientific journal), Joint Work, Accepted, ISSN 0887-6924

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage (>= 20%) and absolute number (>= 2 x 10(9)/l) of plasma cells in the peripheral blood. It is proposed that the thresholds for diagnosis be re-examined and consensus recommendations are made for diagnosis, as well as, response and progression criteria. Induction therapy needs to begin promptly and have high clinical activity leading to rapid disease control in an effort to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens are recommended followed by high-dose therapy with autologous stem cell transplantation if feasible. Allogeneic transplantation can be considered in younger patients. Prospective multicenter studies are required to provide revised definitions and better understanding of the pathogenesis of PCL. Leukemia (2013) 27, 780-791; doi:10.1038/leu.2012.336

Access to Document (DOI)

Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population.

Ueda T, Iino R, Yokoyama K, Okamoto S, Asakura K, Tsukada Y, Ishizawa J, Matsuki E, Ikeda Y and Hattori Y*.

Int J Hematol 96 477-484 2012.10

Research paper (scientific journal), Joint Work

An Anilinoquinazoline Derivative Inhibits Tumor Growth through Interaction with hCAP-G2, a Subunit of Condensin II.

Shiheido H, Naito Y, Kimura H, Genma H, Takashima H, Tokunaga M, Ono T, Hirano T, Du W, Yamada T, Doi N, Iijima S, Hattori Y, Yanagawa H.

PLoS One 7(9) e44889 2012.09

Research paper (scientific journal), Joint Work

A Phthalimide Derivative that is Effective on Multiple Myeloma Inhibits Centrosomal Clustering by Interacting with Nucleophosmin.

Shiheido H, Terada F, Tabata N, Ichigo Hayakawa I, Matsumura N, Takashima H, Ogawa Y, Du W, Yamada T, Shoji M, Sugai T, Doi N, Iijima S, Hattori Y, Yanagawa H.

PLOS One 7(6) e38878 2012.06

Research paper (scientific journal), Joint Work

Isoelectric focusing of urinary transferrin for detection of early stages of diabetic nephropathy.

Sakai N, Kubota R, Shiba K, Hattori Y Iijima S*.

J Electrophoresis 56 1-6 2012.03

Research paper (scientific journal), Joint Work

自家造血幹細胞移植5年後にB細胞性急性リンパ性白血病を発症した多発性骨髄腫.

塚田唯子, 服部豊, 中島秀明, 横山健次, 村田満, 清水長子, 近藤直美, 岡本真一郎

臨床血液 53(2) 219-223 2012.02

Research paper (scientific journal), Joint Work

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Kumar SK ほか International Myeloma Working Group, Hattori Y.

Leukemia 26(1) 149-157 2012.01

Research paper (scientific journal), Joint Work

Bortezomibとアゾール系抗真菌薬の併用後に短期間で麻痺性腸閉塞を発症した多発性骨髄腫.

HATTORI YUTAKA

臨床血液 (日本血液学会) 53 ( 8 ) 760 - 764 2012

Research paper (scientific journal), Joint Work, Accepted, ISSN 0485-1439

Efficacy of Long-Term Treatment with Low-Dose Thalidomide for Patients with Relapsed/Refractory Multiple Myeloma.

Shimizu K, Murakami H, Sawamura M, Hattori Y, Okamoto S, Miwa A, Sugiura I, Shimazaki C, Taniwaki M, Ishida T, Hayashi T, Kosugi H, Yuge M, Iida S, Ishida T, Sunami K, Asaoku H, Sakai A, Abe M, Takagi T.

International Journal of Clinical Medicine 2 570-575 2011.10

Research paper (scientific journal), Joint Work, Accepted

Prospective Study of Combination Therapy with Low-Dose Thalidomide plus Prednisolone Ameliorating Cytopenia in Primary Myelofibrosis.

Hattori Y*, Miyakawa Y, Yokoyama K, Yamada T, Du W, Jinzaki M, Shinmoto H, Okamoto S.

Int J Hematol 93 129-131 2011.01

Research paper (scientific journal), Joint Work

Production of a reactive metabolite of troglitazone by electrochemical oxidation performed in nonaqueous medium.

Tahara K*, Nishikawa T, Hattori Y, Iijima S, Kouno Y, Abe Y.

J Pharm Biomed Anal 50 1030-1036 2009.12

Research paper (scientific journal), Joint Work

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Giralt S ほかInternational Myeloma Working Group, Hattori Y.

Leukemia 23(10) 1904-1912 2009.10

Research paper (scientific journal), Joint Work

　 Previous page - Next page 　